Dr. Leslie Randall Discusses Evidence Supporting BRCA Testing in Ovarian Cancer

Leslie M. Randall, MD
Published: Tuesday, Aug 09, 2016


Leslie M. Randall, MD, associate professor of Gynecology/ Oncology, University of California Irvine, discusses evidence supporting the use of BRCA testing for patients with ovarian cancer.

A strong consensus has been reached in the oncology community that BRCA testing should be performed, although it is not conducted as often as it should be, Randall explains. The level of evidence to support BRCA testing is a level "B," according to the United States Preventive Services Task Force guidelines.

Randall says that, currently, the prevalence of BRCA mutations in ovarian cancer is approximately 20%.

Leslie M. Randall, MD, associate professor of Gynecology/ Oncology, University of California Irvine, discusses evidence supporting the use of BRCA testing for patients with ovarian cancer.

A strong consensus has been reached in the oncology community that BRCA testing should be performed, although it is not conducted as often as it should be, Randall explains. The level of evidence to support BRCA testing is a level "B," according to the United States Preventive Services Task Force guidelines.

Randall says that, currently, the prevalence of BRCA mutations in ovarian cancer is approximately 20%.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x